Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

TriSalus Life Sciences (TLSI) EBIAT (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of EBIAT data on record, last reported at -$9.8 million in Q4 2025.

  • For Q4 2025, EBIAT rose 3.51% year-over-year to -$9.8 million; the TTM value through Dec 2025 reached -$39.2 million, down 30.56%, while the annual FY2025 figure was -$39.2 million, 30.56% down from the prior year.
  • EBIAT reached -$9.8 million in Q4 2025 per TLSI's latest filing, up from -$10.8 million in the prior quarter.
  • Across five years, EBIAT topped out at -$1.4 million in Q3 2023 and bottomed at -$35.6 million in Q4 2023.
  • Average EBIAT over 4 years is -$11.0 million, with a median of -$9.2 million recorded in 2022.
  • Peak YoY movement for EBIAT: skyrocketed 82.39% in 2023, then plummeted 350.65% in 2025.
  • A 4-year view of EBIAT shows it stood at -$22.5 million in 2022, then tumbled by 58.1% to -$35.6 million in 2023, then skyrocketed by 71.64% to -$10.1 million in 2024, then increased by 3.51% to -$9.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$9.8 million in Q4 2025, -$10.8 million in Q3 2025, and -$8.3 million in Q2 2025.